Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Pipeline Review, H2 2017 Summary Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions. Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 5 and 4 respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Bladder Cancer, Melanoma, Renal Cell Carcinoma, Atopic Dermatitis, Breast Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Hematological Tumor, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis. The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects - The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Overview 7 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Development 8 Products under Development by Stage of Development 8 Products under Development by Therapy Area 9 Products under Development by Indication 10 Products under Development by Companies 13 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Therapeutics Assessment 17 Assessment by Mechanism of Action 17 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Companies Involved in Therapeutics Development 23 Abeome Corp 23 Alligator Bioscience AB 23 Apogenix GmbH 24 BioInvent International AB 24 Bristol-Myers Squibb Company 25 Denceptor Therapeutics Ltd 25 Enumeral Biomedical Holdings Inc 26 GlaxoSmithKline Plc 26 Glenmark Pharmaceuticals Ltd 27 Incyte Corp 27 Kyowa Hakko Kirin Co Ltd 28 MedImmune LLC 28 Pfizer Inc 29 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Drug Profiles 30 ATOR-1015 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 BMS-986178 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 durvalumab + MEDI-0562 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 ENUM-004 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Fusion Proteins to Agonize OX40 and NOTCH1 for Type 1 Diabetes - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 GBR-8383 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 GSK-3174998 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 INCAGN-1949 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 KHK-4083 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 MEDI-0562 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 MEDI-0562 + tremelimumab - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Monoclonal Antibodies to Agonize OX40 for Oncology - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Monoclonal Antibody Conjugate to Target OX40L for Transplant Rejection - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Monoclonal Antibody to Agonize OX40L Receptor for Oncology - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 PF-04518600 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Recombinant Protein to Agonize OX40 for Solid Tumor - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 ZL-1101 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Dormant Products 49 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Discontinued Products 50 Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Product Development Milestones 51 Featured News & Press Releases 51 Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015 51 May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015 51 Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4 51 Mar 07, 2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 52 Nov 30, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors 52 Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN-1949 at the American Association for Cancer Research (AACR) 2016 Annual Meeting 53 Nov 03, 2015: GSK and Merck to study immunotherapy combination as potential cancer treatment 53 Sep 21, 2011: AgonOx Receives US Patent For OX40 Ligand Fusion Proteins And Use In Cancer Therapy 54 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56
List of Tables
Number of Products under Development by Stage of Development, H2 2017 8 Number of Products under Development by Therapy Areas, H2 2017 9 Number of Products under Development by Indications, H2 2017 11 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12 Number of Products under Development by Companies, H2 2017 13 Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 16 Number of Products by Stage and Mechanism of Actions, H2 2017 18 Number of Products by Stage and Route of Administration, H2 2017 20 Number of Products by Stage and Molecule Type, H2 2017 22 Pipeline by Abeome Corp, H2 2017 23 Pipeline by Alligator Bioscience AB, H2 2017 23 Pipeline by Apogenix GmbH, H2 2017 24 Pipeline by BioInvent International AB, H2 2017 24 Pipeline by Bristol-Myers Squibb Company, H2 2017 25 Pipeline by Denceptor Therapeutics Ltd, H2 2017 25 Pipeline by Enumeral Biomedical Holdings Inc, H2 2017 26 Pipeline by GlaxoSmithKline Plc, H2 2017 26 Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017 27 Pipeline by Incyte Corp, H2 2017 27 Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 28 Pipeline by MedImmune LLC, H2 2017 28 Pipeline by Pfizer Inc, H2 2017 29 Dormant Projects, H2 2017 49 Discontinued Products, H2 2017 50
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
